AbbVie (ABBV) Deferred Taxes (2019 - 2026)
AbbVie (ABBV) reported Deferred Taxes of $137.0 million for Q1 2026, up 589.29% year-over-year from $19.9 million in Q1 2025, and up 135.58% quarter-over-quarter from -$385.0 million in Q4 2025.
AbbVie (ABBV) Deferred Taxes (2019 - 2026) Analysis & Trends
AbbVie (ABBV) has 8 years of Deferred Taxes data on file, last reported at $137.0 million in Q1 2026.
- Deferred Taxes for Q1 2026 came in at $137.0 million, up 589.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$327.0 million (up 69.94% YoY), and the FY2025 annual result was -$492.0 million, up 66.05% from the prior year.
- Deferred Taxes advanced to $137.0 million in Q1 2026 per ABBV's latest filing, from -$385.0 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $193.0 million in Q3 2025 and troughed at -$1.4 billion in Q4 2023.
- A 5-year average of -$389.6 million and a median of -$368.0 million in 2023 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2022 and 2026: Deferred Taxes slumped 1726.47% in 2022, then soared 589.29% in 2026.
- A 5-year view of Deferred Taxes shows it stood at -$516.0 million in 2022, then plunged by 169.57% to -$1.4 billion in 2023, then jumped by 44.86% to -$767.0 million in 2024, then soared by 49.8% to -$385.0 million in 2025, then surged by 135.58% to $137.0 million in 2026.
- Business Quant data shows ABBV's Deferred Taxes at $137.0 million in Q1 2026, -$385.0 million in Q4 2025, and $193.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 1.48 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 159.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 137.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 161.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137.00 Mn |
| Dec 31, 2025 | -385.00 Mn |
| Sep 30, 2025 | 193.00 Mn |
| Jun 30, 2025 | -272.00 Mn |
| Mar 31, 2025 | -28.00 Mn |
| Dec 31, 2024 | -767.00 Mn |
| Sep 30, 2024 | -277.00 Mn |
| Jun 30, 2024 | -16.00 Mn |
| Mar 31, 2024 | -389.00 Mn |
| Dec 31, 2023 | -1.39 Bn |
| Sep 30, 2023 | -863.00 Mn |
| Jun 30, 2023 | -368.00 Mn |
| Mar 31, 2023 | -267.00 Mn |
| Dec 31, 2022 | -516.00 Mn |
| Sep 30, 2022 | -621.00 Mn |
| Jun 30, 2022 | -600.00 Mn |
| Mar 31, 2022 | -194.00 Mn |
| Dec 31, 2021 | -745.00 Mn |
| Sep 30, 2021 | -34.00 Mn |
| Jun 30, 2021 | -91.00 Mn |